Zydus' arm receives final approval from USFDA for Oseltamivir Phosphate Capsules

27 Feb 2017 Evaluate

Zydus Pharmaceuticals’ subsidiary-- Nesher Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) to market Oseltamivir Phosphate Capsules, USP in strengths of 30mg, 45mg and 75mg.

The drug will be produced at the Nesher Pharmaceuticals USA manufacturing facility located in St. Louis, MO, USA. It is an anti-viral used in the prevention and treatment of influenza virus infection. The estimated sales for Oseltamivir Phosphate Capsules is $382 mn as per IMS December 2016 MAT data.

The group has also received the final approval from the USFDA to market Linezolid Tablets USP, 600 mg. The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

913.90 -7.35 (-0.80%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×